This patient’s tumor organoids also showed an exceptional response to the investigational BET inhibitor CPI-0610 and a good response to the WEE1 inhibitor adavosertib, suggesting additional targetable vulnerabilities. This evidence concerns the gene WEE1 and neoplasm.